U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

MedGen UID:
1718561
•Concept ID:
C5237018
•
Neoplastic Process

Definition

Diffuse large B-cell lymphoma, not otherwise specified that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Professional guidelines

PubMed

Treatment strategies for patients with diffuse large B-cell lymphoma.
Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U
Cancer Treat Rev 2022 Nov;110:102443. Epub 2022 Jul 31 doi: 10.1016/j.ctrv.2022.102443. PMID: 35933930
Refractory DLBCL: Challenges and Treatment.
Goldfinger M, Cooper DL
Clin Lymphoma Myeloma Leuk 2022 Mar;22(3):140-148. Epub 2021 Sep 20 doi: 10.1016/j.clml.2021.09.011. PMID: 34666950
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Susanibar-Adaniya S, Barta SK
Am J Hematol 2021 May 1;96(5):617-629. Epub 2021 Mar 19 doi: 10.1002/ajh.26151. PMID: 33661537Free PMC Article

Recent clinical studies

Etiology

Double-hit lymphoma: optimizing therapy.
Dunleavy K
Hematology Am Soc Hematol Educ Program 2021 Dec 10;2021(1):157-163. doi: 10.1182/hematology.2021000247. PMID: 34889402Free PMC Article
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
Lurain K, Ramaswami R, Mangusan R, Widell A, Ekwede I, George J, Ambinder R, Cheever M, Gulley JL, Goncalves PH, Wang HW, Uldrick TS, Yarchoan R
J Immunother Cancer 2021 Feb;9(2) doi: 10.1136/jitc-2020-002097. PMID: 33608378Free PMC Article
The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.
Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR
Am J Hematol 2016 Oct;91(10):E436-41. Epub 2016 Aug 4 doi: 10.1002/ajh.24485. PMID: 27419920
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, Ciceri F, Baronciani D, Scimè R, Pogliani E, Rambaldi A, Bonifazi F, Dalto S, Bruno B, Corradini P
Leukemia 2012 Mar;26(3):520-6. Epub 2011 Sep 9 doi: 10.1038/leu.2011.240. PMID: 21904377
Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype.
Song KW, Mollee P, Keating A, Crump M
Br J Haematol 2003 Mar;120(6):978-85. doi: 10.1046/j.1365-2141.2003.04203.x. PMID: 12648067

Diagnosis

The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.
Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR
Am J Hematol 2016 Oct;91(10):E436-41. Epub 2016 Aug 4 doi: 10.1002/ajh.24485. PMID: 27419920
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM
Ann Oncol 2014 Nov;25(11):2211-2217. Epub 2014 Sep 5 doi: 10.1093/annonc/mdu443. PMID: 25193992Free PMC Article

Therapy

Epcoritamab: First Approval.
Frampton JE
Drugs 2023 Sep;83(14):1331-1340. doi: 10.1007/s40265-023-01930-4. PMID: 37597091
Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma: What is the Evidence?
Kharfan-Dabaja MA, Yassine F, Moustafa MA, Iqbal M, Murthy H
Hematol Oncol Stem Cell Ther 2022 Dec 23;15(4):168-175. doi: 10.1016/j.hemonc.2021.09.004. PMID: 34699774
Double-hit lymphoma: optimizing therapy.
Dunleavy K
Hematology Am Soc Hematol Educ Program 2021 Dec 10;2021(1):157-163. doi: 10.1182/hematology.2021000247. PMID: 34889402Free PMC Article
Loncastuximab Tesirine: First Approval.
Lee A
Drugs 2021 Jul;81(10):1229-1233. doi: 10.1007/s40265-021-01550-w. PMID: 34143407
Tafasitamab: First Approval.
Hoy SM
Drugs 2020 Nov;80(16):1731-1737. doi: 10.1007/s40265-020-01405-w. PMID: 32946059

Prognosis

Tafasitamab: First Approval.
Hoy SM
Drugs 2020 Nov;80(16):1731-1737. doi: 10.1007/s40265-020-01405-w. PMID: 32946059
Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.
Umakanthan JM, Iqbal J, Batlevi CL, Bouska A, Smith LM, Shostrom V, Nutsch H, William BM, Gregory Bociek R, Lunning M, Bierman P, Younes A, Armitage JO, Vose JM
Br J Haematol 2019 Mar;184(5):744-752. Epub 2018 Dec 5 doi: 10.1111/bjh.15702. PMID: 30520026Free PMC Article
The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.
Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR
Am J Hematol 2016 Oct;91(10):E436-41. Epub 2016 Aug 4 doi: 10.1002/ajh.24485. PMID: 27419920
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, Ciceri F, Baronciani D, Scimè R, Pogliani E, Rambaldi A, Bonifazi F, Dalto S, Bruno B, Corradini P
Leukemia 2012 Mar;26(3):520-6. Epub 2011 Sep 9 doi: 10.1038/leu.2011.240. PMID: 21904377
Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype.
Song KW, Mollee P, Keating A, Crump M
Br J Haematol 2003 Mar;120(6):978-85. doi: 10.1046/j.1365-2141.2003.04203.x. PMID: 12648067

Clinical prediction guides

The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.
Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR
Am J Hematol 2016 Oct;91(10):E436-41. Epub 2016 Aug 4 doi: 10.1002/ajh.24485. PMID: 27419920
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM
Ann Oncol 2014 Nov;25(11):2211-2217. Epub 2014 Sep 5 doi: 10.1093/annonc/mdu443. PMID: 25193992Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...